Evidence map›Paper›PMID 42499790›Full record

ArticleTherapeutic advances in medical oncology2026

A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohort.

Young Kwang Chae, Rosie Sun, Sandip P Patel, Francis Giles, James P Ohr, Francis P Worden, Jennifer M Suga, Aung Naing, Ezra E Cohen, James Wallace and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Young Kwang ChaeMedical Oncology, Translational Medicine, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 645 N. Michigan Ave, Ste. 1006, Chicago, IL 60611, USA.ORCID https://orcid.org/0000-0003-1557-7235
Rosie SunBiostatistics Department, University of Washington, Seattle, WA, USA.
Sandip P PatelMedical Oncology, UCSD Moores Cancer Center, 3855 Health Sciences Drive #0987, La Jolla, CA 92093, USA.
Francis GilesMedical Oncology, Northwestern University, Chicago, IL, USA.
James P OhrHematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Francis P WordenMedical Oncology, University of Michigan, Ann Arbor, MI, USA.
Jennifer M SugaOncology, Kaiser Permanente-Vallejo/NCORP, Vallejo, CA, USA.
Aung NaingDepartment of Investigational Cancer Therapeutics, University of Texas/MD Anderson, Houston, TX, USA.
Ezra E CohenMedical Oncology, University of California at San Diego Moores Cancer Center, La Jolla, CA, USA.
James WallaceHematology Oncology, University of Chicago, Chicago, IL, USA.
Hyun Seok KangMedical Oncology, University of San Francisco, San Francisco, CA, USA.
Sarah FentonMedical Oncology, Northwestern University, Chicago, IL, USA.ORCID https://orcid.org/0000-0002-5102-4948
Liam Il-Young ChungMedical Oncology, Northwestern University, Chicago, IL, USA.ORCID https://orcid.org/0000-0001-6541-793X
Christine M McLeodSWOG Data Operations Center, Seattle, WA, USA.
Helen X ChenCancer Therapy Evaluation Program, National Cancer Institute, Investigational Drug Branch, Bethesda, MD, USA.
Elad SharonCancer Therapy Evaluation Program, National Cancer Institute, Investigational Drug Branch, Bethesda, MD, USA.
Howard StreicherCancer Therapy Evaluation Program, National Cancer Institute, Investigational Drug Branch, Bethesda, MD, USA.
Christopher W RyanMedical Oncology, Oregon Health & Science University, Portland, OR, USA.
Megan OthusSWOG Statistics and Data Management Center, Seattle, WA, USA.
Charles D BlankeSWOG Group Chair's Office, Oregon Health and Science University, Knight Cancer Institute, Portland, OR, USA.
Razelle KurzrockMedical Oncology, Medical College of Wisconsin, MCW Cancer Center/Administrative Office, 9200 West Wisconsin Avenue, Suite C5300, Milwaukee, WI 53226, USA.

Funding

Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MEGAN OTHUS · 2014 to 2026
$115.2M
Northwestern University Lead Academic Participating Site Supplement Year 2UG1CA233320 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BENSON, AL B, MATEI, DANIELA E · 2019 to 2025
$5.5M
NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA233320
6 · The paper itself

Abstract

Background: Anti-programmed death-1 (PD-1)/cytotoxic T lymphocyte antigen-4 antibodies are efficacious in various malignancies. The potential role of dual checkpoint inhibitors in many rare solid tumors is not established. Objectives: This study presents the results of ipilimumab-nivolumab in salivary gland neoplasm cohorts of the SWOG S1609 dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) trial. Design: DART is a prospective, open-label, multicenter (1016 US sites), multi-cohort phase II trial of ipilimumab (1 mg/kg intravenously (IV) every 6 weeks) plus nivolumab (240 mg IV every 2 weeks). Methods: We performed a prospective, multicenter phase II clinical trial of ipilimumab (1 mg/kg IV every 6 weeks) plus nivolumab (240 mg IV every 2 weeks) in three salivary gland neoplasm cohorts: major and minor salivary gland and adenoid cystic cancers. Patients with adenoid cystic salivary gland tumors ( Results: In the adenoid cystic group, objective response rate (ORR), 4% (complete response (CR) 0%, Conclusion: In salivary gland tumors, combined ipilimumab plus nivolumab resulted in only a 4% ORR in adenoid cystic carcinoma and 9% in all other histologies combined, though the latter showed clinical benefit (included SD >6 months) in 35% of patients.

Indexed as

DARTipilimumabnivolumabrare tumorsS1609salivary gland cancer

Identifiers

PMID42499790
PMCPMC13396573

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.